



Date: 13th November, 2017.

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001.

Dear Sir/Madam,

Ref : Script Id "BAJAJHCARE", Script Code "539872".

Sub: Outcome of Board Meeting held on 13th November, 2017 & Submission of financial result for Half Year ended 30th September, 2017.

We hereby inform you that at the meeting of the Board of Directors of our Company held today i.e. 13th November, 2017 has inter alia considered and approved the following:

- Approved Unaudited Financial Result for the Half Year ended on 30th September, 2017 along with Limited Review Report.

We wish to inform you that Board Meeting commenced today at 4.00 pm and concluded at 6.15 p.m.

You are requested to kindly take the same on record.

Thanking you,

Yours faithfully,

For and on behalf of Board of Directors
of Bajaj Healthcare Limited


A handwritten signature in black ink that reads 'Avani Mehta'.

Ms. Avani Mehta
Compliance Officer

BAJAJ HEALTHCARE LTD

Registered Office : 602-606, Bhoomi Velocity Infotech Park, Plot No. B-39, B-39/A, B-39 A/1, Road No. 23, Wagle Ind. Estate, Thane(West), Thane-400 604.
• Tel. : + 91 22 6617 7400 - 499 • Fax : + 91 22 66177458 • Website : www.bajajhealth.com

CIN No.: L99999MH1993PLC072892

**PARESH
RAKESH**

ASSOCIATES
Chartered Accountants

Independent Auditors Review Report

To:


The Board of Directors

Bajaj Healthcare Limited.

1. We have reviewed the accompanying statement of unaudited financial results of **Bajaj Healthcare Limited** for the half year ended 30th September 2017 being submitted by the Company pursuant to the requirement of regulation 33 of the SEBI (Listing and Disclosure Requirements) Regulation, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with accounting standards and other recognized accounting practices and policies generally accepted in India has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Paresh Rakesh & Associates
Chartered Accountants

FRN: 119728W



Rakesh Chaturvedi

Partner

Membership. no 102075

Date: 13th November 2017

Place: Mumbai

BAJAJ HEALTHCARE LIMITED

(CIN No. : L99999MH1993PLC072892)

STATEMENT OF ASSETS & LIABILITIES AS AT 30TH SEPTEMBER 2017

(Rs in Lakhs)


Particulars		As at 30.09.2017	As at 31.03.2017
		(Unaudited)	(Audited)
		₹	₹
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	a) Share Capital	689.96	689.96
	b) Reserves and Surplus	9,772.05	9,210.08
	c) Equity share warrants	-	-
	Sub - Total - Shareholders' Funds	10,462.01	9,900.04
2	Non-current liabilities		
	a) Long - term borrowings	2,426.07	2,684.55
	b) Deferred Tax Liabilities (net)	83.57	84.19
	c) Other long - term liabilities	-	-
	d) Short - term provisions	-	-
	Sub - Total - Non-current Liabilities	2,509.64	2,768.73
3	Current liabilities		
	a) Short - term borrowings	4,469.15	3,915.75
	b) Trade payables	3,288.37	1,885.13
	c) Other current liabilities	2,076.88	2,002.35
	d) Short-term provisions	1,727.08	1,452.08
	Sub - Total - Current Liabilities	11,561.48	9,255.31
	TOTAL - EQUITY AND LIABILITIES	24,533.13	21,924.09
B	ASSETS		
1	Non-Current Assets		
	a) Fixed Assets	12,648.67	12,815.62
	b) Non-Current investments	0.31	0.31
	c) Deferred Tax assets (net)	-	-
	d) Long - term loans and advances	-	-
	Sub - Total - Non-Current Assets	12,648.98	12,815.93
2	Current Assets		
	a) Current investments	-	-
	b) Inventories	2,479.93	1,675.99
	c) Trade receivables	6,555.02	5,268.59
	d) Cash and cash equivalents	43.66	83.98
	e) Short-term loans and advances	-	-
	f) Other current assets	2,805.53	2,079.60
	Sub - Total - Current Assets	11,884.15	9,108.16
	TOTAL ASSETS	24,533.13	21,924.09

Notes

1 The above results were reviewed by the Audit Committee and approved by the Board of Directors of the Company in at their respective meeting held on 13th November 2017

2 The Figures of the Previous year have been Re-grouped, Re-arranged, Re-Classified wherever considered necessary.

By Order of the Board
For Bajaj Healthcare Limited



SKR Bajaj
D.No.: 00225950
Chairman and Managing Director

Date: 13/11/2017
Place: Thane

BAJAJ HEALTHCARE LIMITED
(CIN No. : L99999MH1993PLC072892)

UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR 30th SEPTEMBER 2017

(Rs. In Lakhs)

Particulars	Six Months Ended			Year ended
	30.09.2017	31.03.2017	30.09.2016	31.03.2017
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
I. Revenue from operations	14,881.27	11,772.75	11,292.71	23,065.46
II. Other Operating Income	-	-	-	-
III. Total Revenue (I+II)	14,881.27	11,772.75	11,292.71	23,065.46
IV. Expenses				
(a) Cost of materials consumed (Including Other Direct Expenses)	12,090.28	8,205.87	8,547.71	16,753.57
(b) Changes in Inventories of Finished Good	-356.15	477.53	-162.95	314.58
(c) Employee benefits expense	1,038.11	980.40	976.32	1,956.72
(d) Finance Costs	388.83	386.33	414.26	800.59
(d) Depreciation and amortisation expense	561.23	583.24	551.31	1,134.55
(e) Other expenses	446.62	565.77	409.82	975.59
Total Expenses	14,168.92	11,199.13	10,736.47	21,935.60
V. Profit before exceptional and extraordinary items and tax (III-IV)	712.35	573.62	556.24	1,129.87
4. Other Income	123.99	233.27	5.84	239.11
5. Profit / (Loss) from ordinary activities before exceptional items(3+4)	836.35	806.90	562.08	1,368.98
VI. Exceptional items				
VII. Profit before Extraordinary Items tax (V+VI)	836.35	806.90	562.08	1,368.98
VIII. Extraordinary Items				
IX. Profit Before Tax (VII-VIII)				
X. Tax Expense	274.38	367.72	218.78	586.50
XI. Profit (Loss) for the period	561.97	439.17	343.30	782.47
XII. Profit / (Loss) from discontinuing Operations	561.97	439.17	343.30	782.47
XIII. Tax expenses of discontinuing operations	-	-	-	-
XIV. Profit / (Loss) from discontinuing operations (after tax) (XII-XIII)	-	-	-	-
XV. Profit (Loss) for the period (XI + XIV)	561.97	439.17	343.30	782.47
10. Extraordinary items (net of tax expense)	-	-	-	-
11. Net Profit / (Loss) for the period (9+10)	561.97	439.17	343.30	782.47
12. Paid-up Equity Share Capital (Face Value ₹ 10/-)	689.96	689.96	689.96	689.96
13. Reserves excluding revaluation reserves as per Balance Sheet of Previous accounting Year				9,210.08
XVI. EPS (Not Annualised)				
(a) Basic	8.14	6.38	5.00	11.37
(b) Diluted	8.14	6.38	5.00	11.37

Note :

- The above results were reviewed by the Audit Committee and approved by the Board of Directors of the Company in at their respective meeting held on 13th November 2017
- The Statutory Auditors of the Company has issued Audit Report as required under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 with un-modified opinion.
- The figures for the Half Year ended 30th Sept 2017 are the balancing figures between the audited figures in respect of the full financial years and the published year-to-date figures upto the Half Year Ended of relevant financial year.
- The figures for the previous period have been regrouped whenever necessary.
- The Statement as per Accounting Standard AS - 17 on segment reporting is given as Anneuxre A
- EPS for the Year ending on 30th Sept 2017 has been calculated on Weighted Average 6899600 Equity Shares. EPS for the half year ended 30th Septemebr 2017 has been calculated on Weighted Average 6899600 Equity Shares.

For Bajaj Healthcare Limited


SKR Bajaj
 D.No.: 00225950
 Chairman & Managing Director

Date: 13th November 2017
Place: Thane

BAJAJ HEALTHCARE LIMITED


(CIN No. : L99999MH1993PLC072892)

REPORT ON SEGMENT RESULTS FOR YEAR ENDED 30th Sept, 2017

(Rs. In Lakhs)

Sr No	Particulars	Six Months Ended			Year ended
		30.09.2017	31.03.2017	30.09.2016	31.03.2017
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
A	Segment Revenue				
	Bulk Drugs	14626.25	11,495.01	10,905.08	22,400.09
	Formulations	255.02	277.75	387.63	665.37
	Total	14,881.27	11,772.76	11,292.71	23,065.46
	Less : Intersegment Revenue				
	Bulk Drugs	27.20	39.30	31.13	70.43
	Formulations	-27.20	-39.30	-31.13	-70.43
	Total	-	-	-	-
	Net Sales / Income From Operations				
	Bulk Drugs	14,599.05	11,455.71	10,873.95	22,329.66
Formulations	282.22	317.05	418.75	735.80	
Total	14,881.27	11,772.76	11,292.71	23,065.46	
B	II. Segment Results				
	Profit / (Loss) Before Tax & Finance Cost				
	Bulk Drugs	1690.68	1,706.34	1,478.60	3,184.94
	Formulations	-133.93	-156.08	-92.44	-248.52
	Total	1,556.75	1,550.27	1,386.16	2,936.42
	Less : Interest	388.83	386.33	414.26	800.59
	Other Unallocable Expenditure (Net)	332.07	357.04	409.82	766.86
Net of Unallocable Income	-	-	-	-	
Total Profit Before Tax	835.85	806.90	562.08	1,368.98	
C	III. Capital Employed				
	Segment Assets - Segment Liabilities				
	Bulk Drugs	8874.66	8,192.81	7,667.60	8,192.81
	Formulations	1587.35	1,707.23	1,793.27	1,707.23
Total Capital Employed	10,462.01	9,900.04	9,460.87	9,900.04	

For Bajaj Healthcare Limited



SKR Bajaj
D.No.: 00225950
Chairman & Managing Director

Place : Thane
Date : 13/11/2017